In CRC, BRAF is mutated with a prevalence of 9.6% [3] and the T1799A mutation accounts for more than 80% of these mutation events, resulting in a hyperactivating substitution of valine600 by glutamic acid [4]. Here, BRAF is linked to colorectal carcinoma.